Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?

Therapeutic Drug Monitoring

Volumn 18, Issue 4, 1996, Pages 350-356

  Relling, Mary V ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Anticancer drugs; P glycoprotein; Pharmacokinetics

Indexed keywords

CYCLOSPORIN; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOMYCIN C; MITOXANTRONE; NIFEDIPINE; PACLITAXEL; PROGESTERONE; QUINIDINE; QUININE; TACROLIMUS; TAMOXIFEN; TENIPOSIDE; TRIFLUOPERAZINE; VERAPAMIL; VINCRISTINE;

BILIARY EXCRETION; CANCER CHEMOTHERAPY; CANCER TISSUE; CELL SURVIVAL; CONFERENCE PAPER; DRUG EFFECT; HUMAN; INTESTINE ABSORPTION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEIN;

EID: 0029814123     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199608000-00006     Document Type: Conference Paper

References (38)

1. Houghton PJ, Kaye SB. Multidrug resistance is not an important factor in therapeutic outcome in human malignancies. J NIH Res 1994;6:55-61.
2. Dalton W, Sikic BI. The multidrug-resistance gene (MDR1) represents a potential target for reversing drug resistance in human malignancies. J NIH Res 1994;6:54-8.
3. Gros P, Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-31.
4. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004-8.
5. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-99.
6. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989;16:156-65.
7. Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
8. Berg SL, Tolcher A, O'Shaughnessy JA, et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995;13:2039-42.
9. Sonnichsen DS, Lui Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human CYP450 metabolism of paclitaxel in vitro and in vivo. J Pharmacol Exp Ther 1995;275:566-75.
10. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994;54:4026-35.
11. Zhou X-J, Zhou-Pan X-R, Gauthier T, Placidi M, Maurel P, Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem Pharmacol 1993;45:853-61.
12. Beck WT. Modulators of P-glycoprotein-associated multidrug resistance. In: RF Ozols, ed. Molecular and clinical advances in anticancer drug resistance. Boston: Kluwer Academic Publishers, 1991:151-70.
13. Beck WT. Mechanisms of multidrug resistance in human tumor cells: the roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 1990;17:11-20.
14. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance: a literature review. Cancer 1993;72:3553-63.
15. Kroemer HK, Gautier J-C, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Arch Pharmacol 1993;348:332-7.
16. Jacolot F, Simon I, Dreano Y, Beaune PH, Riche C, Berthou F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991;41: 1911-9.
17. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 -hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988; 263:424-36.
18. Gonzalez FJ, Schmid BJ, Umeno M, et al. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 1988;7:79-86.
19. Guengerich FP, Müller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986;30:287-95.
20. Vincent SH, Karanam BV, Painter SK, Chiu S-HL. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992;294:454-60.
21. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-60.
22. Lum BL, Fisher GA, Brophy NA, et al.. Clinical trials of modulation of multidrug resistance: pharmacokinetic and pharmacodynamic considerations. Cancer 1993;72:3502-14.
23. Dalton WS, Crowley JJ, Salmon SS, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest Oncology Group study. Cancer 1995;75:815-20.
24. Milroy R. West of Scotland Lung Cancer Research Group and the Aberdeen Oncology Group. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Br J Cancer 1993;68:813-8.
25. Wishart GC, Bissett D, Paul J, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 1994;12:1771-7.
26. Kerr DJ, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986;18:239-42.
27. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994;12:835-42.
28. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a Phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-42.
29. Wilson WH, Jamis-Dow C, Bryant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995;13:1985-94.
30. Philip PA, Joel S, Monkman SC, et al. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer 1992;65:267-70.
31. Samuels BL, Mick R, Vogelzang NJ, et al. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther 1993;54:421-9.
32. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993;53:4837-42.
33. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-5.
34. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994;45:352-8.
35. Bachur NR. Adriamycin (NSC-123127) pharmacology. Cancer Chemother Rep 1975;6:153-8.
36. Bachur NR, Gordon SL, Gee MV, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Nail Acad Sci USA 1979;76: 954-7.
37. Berg SL, Cowan KH, Balis FM, et al. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994; 86:143-5.
38. Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E. Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol 1995;35:188-90.